Ubs Group Ag Rain Therapeutics Inc. Transaction History

Ubs Group Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.84 - $1.22 $17,340 - $25,185	20,644 Added 238.74%	29,291 $35,000
Q3 2023 Nov 09, 2023	SELL	$0.82 - $1.42 $1,036 - $1,794	-1,264 Reduced 12.75%	8,647 $7,000
Q2 2023 Aug 11, 2023	BUY	$1.09 - $9.93 $8,797 - $80,145	8,071 Added 438.64%	9,911 $11,000
Q1 2023 May 12, 2023	BUY	$7.77 - $12.47 $7,202 - $11,559	927 Added 101.53%	1,840 $16,000
Q4 2022 Feb 08, 2023	SELL	$5.52 - $8.48 $4,333 - $6,656	-785 Reduced 46.23%	913 $7,000
Q3 2022 Nov 10, 2022	BUY	$4.75 - $8.01 $8,065 - $13,600	1,698 New	1,698 $8,000
Q2 2022 Aug 10, 2022	SELL	$2.21 - $5.56 $1,529 - $3,847	-692 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$5.07 - $13.68 $26,480 - $71,450	-5,223 Reduced 88.3%	692 $4,000
Q4 2021 Feb 14, 2022	BUY	$11.91 - $17.0 $70,447 - $100,555	5,915 New	5,915 $76,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.